Closely-held Fibrocor Therapeutics appointed Joseph Walewicz, a biotech veteran with more than 25 years of experience in finance, capital markets and business development, as CFO.
Prior to joining Fibrocor, Mr. Walewicz was EVP of business and corporate development with Clementia Pharmaceuticals, joining the executive team prior to its NASDAQ IPO in 2017, and through to IPSEN’s $1-billion acquisition of Clementia in 2019. He also has served as an executive at two other publicly-traded biopharma companies, and a ranked investment analyst at major North American investment banks.
In a statement, Mark Steedman, CEO of Fibrocor, said the company expects Mr. Walewicz’s experience in finance, capital markets and business development will be extremely valuable as Fibrocor grows and expands its business.
Mr. Walewicz said Fibrocor’s key development programs are progressing towards clinical development. “I look forward to helping Fibrocor continue to build a world-class development team that will advance its clinical programs, while also expanding and accelerating our innovative discovery efforts in fibrotic diseases.”
